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Abstract Recently, we have shown that the treatment of
cells with proteasome inhibitor MG-132 results in the
induction of expression of monocyte chemotactic protein-1
induced protein 1 (MCPIP1). MCPIP1 is a ribonuclease,
responsible for the degradation of transcripts encoding
certain pro-inflammatory cytokines. The protein is also
known as an inhibitor of NF-jB transcription factor.
Thanks to its molecular properties, MCPIP1 is considered
as a regulator of inflammation, differentiation, and sur-
vival. Using siRNA technology, we show here that
MCPIP1 expression contributes to the toxic properties of
MG-132 in HeLa cells. The inhibition of proteasome by
MG-132 and epoxomicin markedly increased MCPIP1
expression. While MG-132 induces HeLa cell death,
down-regulation of MCPIP1 expression by siRNA partially
protects HeLa cells from MG-132 toxicity and restores
Nuclear factor-jB (NF-jB) activity, inhibited by MG-132
treatment. Inversely, overexpression of MCPIP1 decreased
constitutive activity of NF-jB and limited the survival of
HeLa cells, as we have shown in the previous study.
Interestingly, although MG-132 decreased the expression
of IjBa and increased p65 phosphorylation, the inhibition
of constitutive NF-jB activity was observed in MG-132-
treated cells. Since the elevated constitutive activity of NF-
jB is one of the mechanisms providing increased survival
of cancer cells, including HeLa cells, we propose that
death-promoting properties of MCPIP1 in MG-132-treated
HeLa cells may, at least partially, derive from the negative
effect on the constitutive NF-jB activity.
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Introduction
Monocyte chemotactic protein-1 induced protein 1
(MCPIP1) is a multifunctional protein involved in the
regulation of such processes as macrophage activation [1,
2], cell differentiation [3, 4], and survival [5–7] (reviewed
in [8]). The protein was shown to negatively regulate
inflammation-related processes by the inhibition of Nuclear
factor-jB (NF-jB) transcription factor [1, 9] and endori-
bonucleolytic degradation of transcripts encoding pro-
inflammatory cytokines, i.e., interleukin (IL)-6, IL-1b,
IL12b, and IL-2 [10–12]. Recently, we have shown that the
expression of MCPIP1 is markedly increased in HeLa and
HepG2 cells upon the treatment with proteasome inhibitor
MG-132 [13]. We have also shown that MCPIP1 overex-
pression decreases the survival of HeLa cells [13]. Our
initial data suggested that MCPIP1 expression may par-
tially be involved in toxic properties of MG-132 protea-
some inhibitor.
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The inhibition of proteasome became an extensively
studied strategy in cancer treatment due to the importance
of ubiquitin–proteasome system in the promotion of cell
cycle progression and activation of NF-jB signaling
pathway as well as removal of tumor suppressor protein
p53 [14]. Within past years, numerous studies showed the
astonishing potency of proteasome inhibitors to induce
cancer cell death. Up to date, thousands of proteasome
inhibitors have been developed (reviewed in [15]), among
which several entered clinical trials, and two, namely
bortezomib (PS-341/Velcade) [16] and carfilzomib [17],
have been approved by US Food and Drug Administration
for the treatment of multiple myeloma patients [18–20].
The mechanism of proteasome inhibition-induced toxicity
relies on several events, among which the induction of
endoplasmic reticulum stress and unfolded protein
response play a major role, with accompanying deleterious
functions of reactive oxygen species production, NF-jB
inhibition and inhibition of the degradation of cell cycle
regulators and pro-apoptotic factors [21–23].
The exact effect of proteasome inhibition on NF-jB
activity requires deeper verification since up-to-date
reports seem to be contradictory. Many studies proved for
the inhibitory effect of such compounds as bortezomib or
MG-132 on TNFa and IL-1b-induced NF-jB [24–26] or
constitutive NF-jB activity [27, 28]. Contrary to these
findings, several reports pointed that both bortezomib and
MG-132 alone may lead to the degradation of IjBa protein
[29–31] and activation of NF-jB [29, 32]. In the present
study, we verify the impact of proteasome inhibitor MG-
132 on IjBa expression and the activity of NF-jB tran-
scription factor. We also correlate our observations with
the induction of MCPIP1 expression upon MG-132 treat-
ment and with the deleterious character of this protein
toward tested HeLa cell line.
Results
Proteasome inhibitor epoxomicin increases
the expression of MCPIP1
We have shown recently that the inhibition of proteasome
with MG-132 results in transcription-dependent increase of
MCPIP1 protein [13]. Besides the inhibition of proteasome,
at the higher concentrations MG-132 (ZLLLal) inhibits
calpains and cathepsins [15, 33]. Although the dose used in
our study (1 lM) was below IC50 of calpain inhibition, we
verified the observed effect of MG-132 on MCPIP1
expression level using epoxomicin—the most specific and
potent proteasome inhibitor known [15]. Epoxomicin
increased the expression of MCPIP1 protein in HeLa cells
at the time points 5 and 6 h of the treatment (Fig. 1a, b).
Similarly, in HepG2 cells the increase of MCPIP1
expression was observed after 6 h of epoxomicin treatment
(Fig. 1c). Interestingly, unlike in the case of MG-132 [13],
the level of MCPIP1 expression dropped down to the basal
level after 24 h since the administration of epoxomicin in
both tested cell lines (Fig. 1b, c).
Proteasome inhibition by MG-132 results
in the phosphorylation-dependent degradation of IjBa
It has been reported that prolonged inhibition of protea-
some with bortezomib or MG-132 results in caspase-8 and/
or calpain-dependent degradation of IjBa [30, 31]. To
verify the impact of MG-132 on IjBa expression, HepG2
and HeLa cells were treated with 1 lM MG-132 for 1, 6, or
24 h. The treatment of the cells for 1 h did not change the
expression level of IjBa (Fig. 2a, b). In contrast, exposi-
tion of cells to MG-132 for 6 h resulted in a decrease of
IjBa quantity in both cell lines tested, and the treatment of
cells for 24 h resulted in a total disappearance of IjBa
(Fig. 2a, b).
Consecutive phosphorylation, ubiquitination, and pro-
teasomal degradation of IjBa are important events for the
activation of the canonical NF-jB pathway. To verify if
MG-132 treatment increases IjBa phosphorylation prior to
the protein disappearance, HeLa cells were treated with
1 lM MG-132 for 30 min or 1, 2, 4, or 6 h, and western
blot detection of phospho-IjBa was performed (Fig. 2c).
The stimulation with 10 ng/ml of IL-1 b for 15 min,
serving as a positive control, resulted in phosphorylation of
IjBa and its almost complete removal (Fig. 2c). The
treatment of HeLa cells with MG-132 strongly and time-
Fig. 1 Proteasome inhibitor, epoxomicin, increases the expression of
MCPIP1. a–c HepG2 or HeLa cells (as indicated) were treated with
100 nM epoxomicin or DMSO for the indicated time periods. Protein
extracts were subjected to western blotting with antibodies specific
for MCPIP1 and a-tubulin. Blots are representative from three
independent experiments
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dependently increased the phosphorylation of IjBa
(Fig. 2c). Additionally, as a hallmark of NF-jB activation,
we verified the phosphorylation of p65 subunit of NF-jB at
the position Ser536. Both IL-1b and MG-132 treatment
resulted in the phosphorylation of p65 (Fig. 2c). The
phosphorylation of p65 in MG-132-treated cells developed
with time but at the longest time tested (6 h) was at least
four times weaker than phosphorylation observed in IL-1b-
treated cells (Fig. 2c).
Previously, it has been proposed that the mutant variant
of IjBa deprived of two phosphorylation sites at the
positions Ser32 and Ser36, which is resistant to protea-
some-mediated degradation, is also resistant to MG-132-
triggered degradation [31]. To test this, we took advantage
of two cell lines stably transduced with an empty virus
(HepG2-mock cell line) or a virus encoding IjBa(S/A)—a
mutant of IjBa protein bearing two mutations at the
mentioned serine residues (HepG2- IjBa(S/A) cell line)
[34]. Overexpression of the IjBa(S/A) mutant resulted in
the decrease of endogenous IjBa expression when com-
pared to untreated mock cell line (Fig. 2d, lanes 3 and 4
compared to 1 and lanes 7 and 8 compared to 5).The
treatment of HepG2-mock cells with MG-132 decreased
the level of endogenous IjBa expression, both after 8 and
24 h of treatment (Fig. 2d, lanes 2 and 6 compared to 1 and
5, respectively). In HepG2-IjBa(S/A) cell line, a strong
IjBa-specific signal was observed just above the signal
corresponding to endogenous IjBa, reflecting the expres-
sion of the transgene (IjBa(S/A) protein). The expression
of IjBa(S/A) was not decreased following MG-132 treat-
ment, which suggests that the IjBa mutant is indeed
resistant to the degradation observed after prolonged pro-
teasome inhibition (Fig. 2d, lanes 4 and 8 compared to 3
and 7, respectively).
Upon the treatment of HepG2-mock cells with MG-132,
a strong increase of MCPIP1 expression was observed at
both time points tested: 8 and 24 h (Fig. 2d). Similarly, in
HepG2-IjBa(S/A) cells MCPIP1 expression increase,
comparable to mock cell line, was observed (Fig. 2d).
The inhibition of proteasome by MG-132 decreases
constitutive activity of NF-jB
The removal of IjBa and phosphorylation of the p65
subunit following MG-132 treatment suggest the possibil-
ity of NF-jB activation. In order to verify the activity of
NF-jB following MG-132 treatment, a secreted alkaline
phosphatase (SEAP)-based NF-jB promoter activity test
was performed on cells transfected with a vector containing
a SEAP-coding gene under the control of four NF-jB-
binding sites (plasmid pNFjB-SEAP). The cells were
treated with DMSO or MG-132 for 2, 4, 6, 8, 16, or 24 h,
and the accumulation of SEAP in media was measured
using luminescence-based method.
The activity of SEAP in culture media from DMSO-
treated cells increased with time due to a constitutive NF-
jB activity (Fig. 3a, white bars). Interestingly, the treat-
ment of cells with MG-132 resulted in 20–60 % lower
accumulation of SEAP starting from the 6th hour of the
treatment in case of HepG2 cells and the 8th hour of
treatment in case of HeLa cells (Fig. 3a, black bars versus
white bars). This suggests the inhibition of NF-jB by
prolonged MG-132 treatment rather than its activation. To
verify the expression of MCPIP1 and IjBa in cells
Fig. 2 Proteasome inhibitor MG-132 leads to phosphorylation-
dependent removal of IjBa. a, b HepG2 or HeLa cells (as indicated)
were treated with 1 lM of MG-132 or DMSO for the indicated time
periods and subjected to western blotting against IjBa and a-tubulin.
c HeLa cells were treated with 10 ng/ml of IL-1b, 1 lM of MG-132
or DMSO for the indicated time periods and subjected to western
blotting against P-p65, p65, P-IjBa, IjBa, and a-tubulin. d Two
HepG2 stable cell lines: IjBa(S/A), overexpressing dominant nega-
tive mutant of IjBa protein deprived of phosphorylation sites Ser32
and Ser36, and control mock cell lines were treated with MG-132 or
DMSO for 8 or 24 h. Protein lysates were collected and subjected to
western blotting with the indicated antibodies. The blots presented
here are representative of three experiments
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transfected with SEAP-coding plasmid, a western blot was
performed. As expected, the treatment resulted in a time-
dependent increase of MCPIP1 protein and time-dependent
decrease of IjBa, in accordance with the results presented
in previous sections (Fig. 3b).
MCPIP1 decreases both constitutive and IL-1b-induced
transcriptional activity of NF-jB
Previously, we and others have reported that MCPIP1
inhibits NF-jB transcription factor activity [1, 9]. The NF-
jB-inhibitory properties of MCPIP1 have been assigned to
the enzymatic domain named PIN/DUB [35]. To addi-
tionally verify the effect of MCPIP1 on NF-jB-driven
transcription and to test the requirement of PIN/DUB
domain in this process, a SEAP activity test was per-
formed. For this, HepG2 and HeLa cells were co-trans-
fected with the pNFjB-SEAP vector and two amounts of
plasmid encoding MCPIP1-myc protein, the protein variant
deprived of PIN/DUB domain (DPIN/DUB-myc) or an
empty vector. To minimize the toxic properties of MCPIP1
in transfected cells, the amount of plasmid encoding
MCPIP1 proteins was limited to 15 and 30 % of total DNA
used in transfection. The mixture of SEAP-coding plasmid
and empty plasmid constituted the remaining 85 or 70 %.
The cells were stimulated with IL-1b for 24 h and SEAP
accumulation in the medium was measured using lumi-
nescence-based assay. The expression of MCPIP1-myc and
DPIN/DUB-myc proteins in transfected cells was verified
by western blot (Fig. 4c).
The stimulation of HepG2 and HeLa cells transfected
with an empty vector with IL-1b resulted in a 5- and 4-fold
increase of SEAP activity in the medium, respectively
(Fig. 4a, b). This SEAP activity increase was inhibited very
strongly and dose-dependently by the expression of
MCPIP1-myc protein (Fig. 4a, b). In contrast, the expres-
sion of DPIN/DUB-myc protein in HeLa cells failed to
inhibit the effect of IL-1b on NF-jB-dependent SEAP
accumulation (Fig. 4b).
Notably, besides IL-1b-stimulated NF-jB-dependent
expression, the presence of MCPIP1-myc protein signifi-
cantly and dose-dependently decreased also the basal level
of SEAP activity in both cell lines tested, suggesting the
involvement of MCPIP1 in the inhibition of constitutive
NF-jB activity (Fig. 4a, b).
MCPIP1 silencing increases NF-jB activity
and partially protects HeLa cells from MG-132 toxicity
As we have shown previously increased expression of
MCPIP1 decreases the survival of HeLa cells [13]. In order
to verify, the involvement of the elevated MCPIP1 in the
toxicity of MG-132 toward HeLa cells siRNA technology
was applied. For this, HeLa cells cultured on Ø 60 mm
culture dishes were transfected with negative siRNA
(depicted as neg.si) or MCPIP1 siRNA (depicted as
Fig. 3 MG-132 inhibits NF-jB-dependent expression. a HepG2 or
HeLa cells were transfected with the plasmid containing SEAP-
encoding gene under the control of four jB sites (pNFjB-SEAP
vector). After 48 h, the cells were treated with 1 lM of MG-132 for
the indicated time periods. Media were collected for the measurement
of accumulated SEAP activity and the cells were lysed and subjected
to western blotting with antibodies specific for MCPIP1, IjBa, and a-
tubulin (b). Graphs show fold change of SEAP activity versus
DMSO-treated control at the time point 2 h and are mean ± SE from
three experiments. Blots are representative from two experiments
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MCPIP1.si) and cultured for 72 h. Then, the cells were
seeded on culture plates for the experiments. Next day,
cells were treated with 1 lM of MG-132 and survival and
toxicity were measured after 24 h using MTT test, ATP
content, propidium iodide/Hoechst double staining, and
caspase 3/7 activity (Fig. 5). Parallely, the silencing of
MCPIP1 expression was verified in siRNA-transfected and
cultured cells by western blotting, after 6 h of treatment
with DMSO or 1 lM MG-132 (Fig. 5a).
The treatment of neg.si1-transfected control HeLa cells
with 1 lM MG-132 decreased the viability of cells by
around 30 %, when analyzed by MTT or ATP content test
(Fig. 5b, c). MG-132 treatment resulted in a 10-fold
increase of the number of dead propidium iodide-positive
cells, from 1.5 to 15 %, and resulted in a 7.5-fold increase
of the activity of caspase 3/7 (Fig. 5d, e). siRNA-mediated
down-regulation of MCPIP1 expression in HeLa cells did
not significantly change the basal metabolism nor viability,
as revealed by MTT test and ATP content measurement
(Fig. 5b, c, white bars, P = 0.26, n = 4 and P = 0.15,
n = 3 for MTT and ATP content respectively). In contrast,
propidium iodide staining revealed a faint but significant
decrease of dead cells after MCPIP1 silencing (Fig. 5d,
white bars), while a weak but significant increase of cas-
pase 3/7 activity was observed in MCPIP1.si- versus
neg.si-transfected cells (Fig. 5e, white bars).
More importantly, knock-down of MCPIP1 by siRNA
resulted in a significant protection of HeLa cells against
MG-132 toxicity. In MTT test, the viability of analyzed
cells was increased by 8 % and in ATP content test by
20 % (Fig. 5b, c, black bars). MCPIP1-specific siRNA
decreased also the number of propidium iodide-positive
cells from 14.9 to 11.7 % after MG-132 treatment (Fig. 5d,
black bars). No significant change in caspase 3/7 activation
was observed in the cells treated with MCPIP1.si in com-
parison to neg.si-transfected cells (Fig. 5e, black bars,
P = 0.20, n = 3).
MCPIP1 is known to inhibit NF-jB activation. To verify
the engagement of elevated MCPIP1 in NF-jB inactivation
by MG-132, HeLa cells were transfected with MCPIP1.si
or neg.si siRNAs together with pNFjB-SEAP reporter
vector. Next day, the cells were treated with MG-132
inhibitor, and SEAP activity test was performed.
Silencing of MCPIP1 expression by siRNA resulted in
a strong and significant increase of SEAP accumulation in
both DMSO- and MG-132-treated cells (Fig. 5f, white
bars and black bars). The treatment with MG-132 of both
neg.si1-transfected and MCPIP1.si-transfected cells
decreased the accumulation of SEAP in the medium by
54 and 64 %, respectively (Fig. 5f). Importantly, in
MCPIP1-silenced and MG-132-treated cells, the measured
activity of SEAP was comparable to its activity in
DMSO-treated neg.si-transfected cells, suggesting the
restoration of disturbed NF-jB by MCPIP1 down-regu-
lation (Fig. 5f).
To confirm the NF-jB inhibitory properties of MCPIP1
in HeLa cells, we investigated the early stages of the
activation of this transcription factor, i.e., IjBa degrada-
tion and phosphorylation of IjBa and p65, in MCPIP1-
silenced HeLa cells stimulated with TNFa and IL-1b
(Fig. 5g–h). Short times of cell stimulation were chosen to
avoid: (a) total degradation of IjBa in neg.si-transfected,
Fig. 4 MCPIP1 inhibits NF-jB-dependent expression of reporter
gene, both at the constitutive and IL-1b-induced NF-jB activity level.
HepG2 cells a or HeLa cells b were transfected with pNFjB-SEAP
vector together with plasmids encoding MCPIP1-myc or DPIN/DUB-
myc protein or an empty vector. Two days following transfection the
cells were stimulated with 10 ng/ml of IL-1b for 24 h. Media were
collected and luminescence-based SEAP activity assay was
performed. The expression of MCPIP1 and DPIN/DUB-myc in tested
cells was verified by western blot (c). Graphs show means ± SE from
three experiments, presented as fold change versus empty vector-
transfected control. For the statistics t test was performed: *P \ 0.05
versus vector-transfected IL-1b-treated cells; #P \ 0.05, ##P \ 0.01
versus vector-transfected DMSO-treated control cells
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cytokine-treated cells, and (b) degradation of MCPIP1,
which has been recently shown by others in HeLa cells
treated with IL-1b [36].
The stimulation of HeLa cells with TNFa and IL-1b
resulted in the marked increase of IjBa phosphorylation in
both neg.si and MCPIP1.si-transfected cells (Fig. 5g–h).
Notably, the degradation of IjBa was not observed in the
control cells, suggesting that the time point between IKK
activation and IjBa degradation was caught. Importantly, at
that time point in MCPIP1.si-transfected cells treated with
10 ng/ml of TNFa or IL-1b already c.a. 40 % of IjBa was
degraded. This suggests, that the deprivation of MCPIP1
expression facilitates the activation of NF-jB in HeLa cells
following the treatment with each of the two stimulants used.
The decreased amount of P-IjBa in MCPIP1.si-treated
cells was observed (Fig. 5g–i). This may be the result of
faster removal of phosphorylated IjBa in MCPIP1-
deprived cells. Importantly, the phosphorylation of p65 was
stronger in MCPIP1-deprived cells, suggesting really
stronger NF-jB activation in comparison to neg.si-trans-
fected cells.
Noteworthy, the expression of basal IjBa was lower in
MCPIP1.si-transfected cells than in control cells. This may
be the symptom of the formation of new regulatory balance
in basal NF-jB activity, introduced by the withdrawal of
constant inhibition of NF-jB by MCPIP1 in MCPIP1-
silenced cells. However, considering the complexity of
feedback loops regulating NF-jB, the accurate cause-effect
interpretation of this phenomenon is not possible basing on
the presented data.
Discussion
Increased constitutive activity of NF-jB transcription fac-
tor is found in a large number [37] if not most tumor cells
[38], providing resistance to apoptosis and promoting
tumor growth. Initially, it has been proposed that the
inhibition of constitutive NF-jB activity is responsible for
the observed toxic effects of proteasome inhibition against
cancer cells. Nowadays, due to the contradictory reports
concerning the impact of proteasome inhibitors on NF-jB
activity, this aspect of proteasome inhibition requires pro-
found re-examination.
In our study, the treatment of both HepG2 and HeLa
cells with MG-132 led to a disappearance of IjBa protein.
This IjBa removal was accompanied by its strong phos-
phorylation. This phosphorylation seems to be important
for the observed degradation of IjBa, since dominant
negative variant of this protein, bearing two serine-to-ala-
nine substitution at the phosphorylated positions 32 and 36,
was resistant to MG-132-induced degradation. Similar
observation was reported before by another group [31].
Thus, upon proteasome inhibition, IjBa undergoes phos-
phorylation-dependent degradation, but in an impaired
fashion, due to the inactivation of ubiquitin–proteasome
system. The slow degradation of IjBa in such instance
may be executed by caspase 8 [30], calpains [31],
remaining proteasome activity or by another, yet undeter-
mined protease.
Besides the phosphorylation of IjBa, MG-132 treatment
resulted in the phosphorylation of p65 subunit of NF-jB.
Unexpectedly, while both IjBa degradation and p65
phosphorylation are the hallmarks of NF-jB activation, we
observed a decrease of NF-jB-driven reporter gene
expression in both cell lines treated with MG-132. This
suggests that MG-132 does not activate but inhibits con-
stitutive NF-jB activity. This observation seems to be in
accordance with a recent report, showing that although
another proteasome inhibitor, carfilzomib, induced the
disappearance of IjBa, it failed to activate the expression
of some tested classical target genes of NF-jB [39].
b Fig. 5 MCPIP1 silencing partially protects HeLa cells against MG-
132 toxicity and inhibition of constitutive NF-jB activity. a–e For the
study of the involvement of MCPIP1 in MG-132 toxicity HeLa cells
were transfected with MCPIP1-silencing siRNA (MCPIP1.si) or
negative control siRNA (neg.si). Cells were cultured for 3 days on
culture dish and seeded for the experiments. Next day, the cells were
subjected to downstream procedures. a The silencing of MCPIP1 was
verified by western blot in the cells treated with DMSO or MG-132
for 6 h. b–e siRNA-transfected cells were treated for additional 24 h
with DMSO or 1 lM MG-132, followed by MTT test (b) and ATP
content analysis (c). d Following the treatment the cells were double-
stained with Hoechst and propidium iodide. The graph shows the
percentage of dead cells within total population analyzed. e Following
the treatment caspase 3/7 activity was measured using luminescence-
based assay. Graphs b–e represent mean ± SE from three experi-
ments, each performed at least in triplicates. For the statistics, t-test
was performed: *P \ 0.05 versus neg.si-transfected MG-132-treated
cells, **P \ 0.01 versus neg.si1-transfected MG-132-treated cells, #-
P \ 0.05 versus neg.si1-transfected control DMSO-treated cells,
n = 3. f HeLa cells were transfected with negative siRNA (neg.si)
or siRNA for MCPIP1 (MCPIP1.si). Next day the cells were
transfected with pNFjB-SEAP reporter vector and cultured for
24 h. Then, the cells were treated with DMSO or 1 lM MG-132 for
additional 24 h before SEAP activity measurement. Graph shows
mean ± SE from three experiments, each performed in triplicates.
For the statistics t-test was performed: **P \ 0.01 versus neg.si-
transfected DMSO-treated cells, ##P \ 0.01 versus MCPIP1.si-trans-
fected DMSO-treated cells, $P \ 0.05 versus neg.si1-transfected MG-
132-treated cells, n = 3. g–i MCPIP1 silencing improves the
induction of early stages of cytokine-induced NF-jB activation.
HeLa cells were treated with siRNA and cultured for 3 days as
described in figures a–e caption. The cells were seeded and, after
24 h, stimulated with the indicated concentrations of cytokines for
8 min (TNFa) or 5 min (IL-1b). Whole cell lysates were subjected to
western bloting with indicated antibodies. The blots g, h are
representative of two experiments. i semi-quantification of blots g,
h normalized to untreated control (for total IjBa) or control cells
treated with 10 ng/ml of cytokine (P-IjBa/total IjBa and P-p65/total
p65). Graphs show mean ± SE from two experiments
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Moreover, the authors reported no increase in the nuclear
localization of NF-jB subunits p50, p65, or p52 [39]. The
results presented by these authors, together with our results
presented here, indicate that proteasome inhibition leads to
IjBa removal and aberrant activation of NF-jB, which
does not simply translate into transcriptional activity of this
transcription factor.
While it is a surprising but general rule that prolonged
inhibition of proteasome leads to the degradation of IjBa,
the resulting effect on NF-jB activity seems to be both
time- and cell type-dependent. In our study on HeLa and
HepG2 cells, decrease of NF-jB activity was observed. A
study by Hideshima and co-workers shows that the inhi-
bition of basal NF-jB following bortezomib treatment is
observed in cell lines presenting high or moderate consti-
tutive activity of NF-jB (MM.1S and U226), while in the
cells with low constitutive NF-jB bortezomib induced the
activation of this transcription factor [40]. Importantly, of
these three cell lines, MM.1S was shown to be the most
susceptible to bortezomib toxicity [41], which may reflect
the requirement for NF-jB activity for the cell survival.
Similarly, in pancreatic cancer cell line BxPC-3 and
squamous cell carcinoma cell line PAM-LY2, which
present high level of constitutive NF-jB activity, NF-jB
was inhibited by the treatment with MG-132 and bortezo-
mib, respectively [27, 28]. In contrast, the treatment of
MIA PaCa 2 cell line (low constitutive NF-jB activity)
with MG-132 does not change the observed NF-jB status
[28]. Therefore, we postulate that proteasome inhibition
leads to the inhibition of constitutive NF-jB in cell lines in
which increased constitutive activity of this transcription
factor is observed.
We have shown before that the inhibition of proteasome
with MG-132 leads to a potent induction of the expression
of MCPIP1 in two cell lines analyzed, i.e., HeLa and
HepG2 [13]. Here, we support this finding by the use of
epoxomicin, the most specific proteasome inhibitor known.
MCPIP1 possesses toxic properties as shown in studies on
several cell lines [3, 5, 42], including HeLa cell line [13].
Here, we show that silencing of MCPIP1 expression par-
tially protects HeLa cells against MG-132 toxicity, as
revealed by MTT test, ATP content assay and propidium
iodide staining. Thus, MCPIP1 expression contributes to
the toxic properties of MG-132 toward HeLa cells.
Importantly, in HeLa cells the inhibition of NF-jB was
shown to limit the proliferation and survival [43]. As
shown here and in other studies, MCPIP1 inhibits NF-jB
following treatment of cells with LPS, IL-1b [1, 9].
Noteworthy, besides cytokine- or LPS-stimulated NF-jB,
MCPIP1 is also able to inhibit the constitutive activity of
endogenous NF-jB. Vector-based studies on NF-jB-dri-
ven transcription clearly show that not only activated, but
also basal NF-jB-dependent expression is inhibited by the
overexpression of MCPIP1 (Fig. 4 in this manuscript, see
also Fig. 6 in [1], Fig. 5b in [44] and Fig. 3b in [35]). In
our study, MG-132 treatment decreased the activity of NF-
jB, and the inhibition of MCPIP1 expression by siRNA
restored NF-jB activity in MG-132-treated cells. There-
fore, MCPIP1 is an inhibitor of NF-jB transcription factor,
induced in MG-132-treated cells, which results in the
inhibition of constitutive NF-jB. This action of MCPIP1
contributes to the toxicity of MG-132 in HeLa cells, which
survival depends on increased constitutive NF-jB activity.
Due to its known NF-jB inhibitory and immunosup-
pressive properties, MCPIP1 represents a promising target
in anti-cancer therapy. In this study, we provided initial and
preliminary results, suggesting the possible toxic properties
of MCPIP1 toward cancer cells and engagement of
MCPIP1 in the toxicity of MG-132 proteasome inhibitor.
We propose the interplay between MCPIP1 and NF-jB and
its importance in regulation of cancer cell survival. How-
ever, more work needs to be done to verify the usefulness
of this protein in therapeutical approaches.
Materials and methods
Materials
MG-132 inhibitor was from Tocris Bioscience. Epoxomi-
cin was from Sigma Aldrich. Plastic materials were from
BD Falcon. Both MG-132 and epoxomicin were dissolved
in DMSO, thus as a control DMSO was used.
The genetic constructs encoding human MCPIP1 protein
(cloned into pcDNA3.1myc/His (MCPIP1-myc) and
MCPIP1 deprived of PIN/DUB domain cloned into
pcDNA3.1myc/His vector (DPIN/DUB-myc)) were kindly
provided by Danuta Mizgalska, PhD, Faculty of Biophys-
ics, Biochemistry, and Biotechnology, Jagiellonian Uni-
versity, Krakow, Poland [11].
pNFjB-SEAP plasmid (Clontech), used for the studies
on NF-jB-dependent gene expression, was a kind gift from
Prof. Alicja Jozkowicz from the Faculty of Biophysics,
Biochemistry, and Biotechnology, Jagiellonian University,
Krakow, Poland.
Cell culture and treatment
Human hepatocellular liver carcinoma cell line (HepG2)
and Human epithelial carcinoma cell line (HeLa) were
purchased from ATCC collection. HepG2 cells from pas-
sages 95–105 were used. Both cell lines were cultured and
seeded for the experiments as described before [13].
HepG2 cells stably transduced with a retroviral vector
encoding GFP alone (HepG2-mock cell line), or encoding
both GFP and dominant negative mutant of IjBa inhibitor
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(HepG2-IjBa(S/A) cell line), were kindly provided by
Prof. Stephan Ludwig from Heinrich-Heine University,
Düsseldorf, Germany [34]. The transduced cells were
cultured in DMEM containing 1 g/l glucose and 5 % FBS
in a humidified atmosphere at 37 C and 5 % CO2 and
passaged at c.a. 70–80 % of confluence.
Cell transfection
For MCPIP1-myc and DPIN/DUB-myc over-expression,
cells were transfected with Lipofectamine 2000 (Life
Technologies) according to manufacturer’s instructions. To
reduce, the toxicity of Lipofectamine 2000 the medium
was exchanged 4 h following transfection.
For MCPIP1 silencing new technology of modified and
thus more stable Stealth RNAi siRNAs was used (Life
Technologies). The cells were transfected with MCPIP1
specific siRNA (UAUCUUUGGUUU-
GUGGGUUUCCUUC, GC content 40 %) or low GC
content negative siRNA (GC content 36 %) using Lipo-
fectamine 2000 according to manufacturer’s recommen-
dations. HeLa cells growing on Ø 60 mm cell culture
dishes at the confluence of 40–50 % were transfected. For
the transfection, 200 pmol of siRNA was mixed with
500 ll of Opti-MEM medium, and separately 10 ll of
Lipofectamine 2000 was mixed with 500 ll of Opti-MEM
and incubated for 5 min at room temperature. After that,
Lipofectamine-containing Opti-MEM was added to siR-
NA-containing Opti-MEM and incubated at room temper-
ature for 20 min. Then, the prepared mixture was added
dropwise to the culture dish, the dish was rocked gently and
incubated in cell culture incubator for 5 h. The medium
was exchanged to fresh culture medium, and cells were
cultured for additional 3 days and seeded for downstream
experiments.
Western blotting
For the detection of proteins, total cell lysates were pre-
pared using RIPA buffer (25 mM Tris•HCl, pH 7.6,
150 mM NaCl, 1 % NP-40, 1 % sodium deoxycholate,
0.1 % SDS) with protease inhibitor cocktail (Sigma
Aldrich). For the analysis of phosphorylated proteins,
RIPA buffer was additionally supplemented with phos-
phatase inhibitor cocktail (PhosSTOP, Roche). Protein
separation on 12 % SDS-Page polyacrylamide gel and
western blot procedure was performed as described before
[13].
The following antibodies and dilutions were used: rabbit
monoclonal anti-P-IjBa (Ser32) (1:2000, Cell Signaling,
cat. 2859), rabbit monoclonal anti-IjBa (1:10 000, Abcam,
cat. ab32518), rabbit polyclonal anti-MCPIP1 (1:3 000,
GeneTex, cat. GTX110807), rabbit monoclonal anti-
phospho-p65 (Ser536) (1:1,000, Cell Signaling, cat. 3033),
rabbit polyclonal anti-p65 (0.5 lg/ml, Abcam, cat.
ab16502), rabbit polyclonal anti-Myc-Tag (1:2 000, Cell
Signaling, cat. 2272), mouse anti-a-tubulin (1:2 000, Cal-
biochem, cat. CP06), goat peroxidase-conjugated anti-
rabbit (1:3 000, Cell Signaling, cat. 7074), and goat per-
oxidase-conjugated anti-mouse (1:20 000, BD Pharmino-
gen, cat. 554002). The densitometry analysis was
performed with ImageJ 1.40 g software [45].
Secreted alkaline phosphatase (SEAP) activity assay
For the analysis of NF-jB-driven gene expression, a
secreted alkaline phosphatase (SEAP)-based assay was
performed. HepG2 or HeLa cells were seeded on 48-well
plates and transfected with vectors encoding MCPIP1-myc
or DPIN/DUB-myc protein or empty vector (0.1 lg (30 %
of total DNA mass) or 0.05 lg (15 %) of total DNA mass)
together with reporter pNFjB-SEAP plasmid (0.15 lg) and
the empty vector (0.05 or 1 lg, depending on the amount
of MCPIP1-encoding vector) to give final DNA amount:
0.3 lg. Two days following transfection, the cells were
stimulated with IL-1b in the total medium volume of
300 ll for additional 24 h and the enzymatic activity of
SEAP in the medium was measured using Phospha-Light
System (Applied Biosystems). The assay was performed
following the manufacturer’s instructions, but reagents
volumes were limited to 40 %. During the procedure, the
medium was diluted three times with 1 9 Dillution Buffer.
The results were normalized to the survival of transfected
cells measured by MTT assay (the survival was: for HepG2
cells, 15 % MCPIP1-myc plasmid: 102.3 ± 11.4 %, 30 %
MCPIP1-myc plasmid: 94.4 ± 1.4 %; for HeLa cells, 15 %
MCPIP1-myc plasmid: 97.0 ± 2.8 %, 30 % MCPIP-myc
plasmid: 94.2 ± 5.8 %, 15 % DPIN/DUB-myc plasmid:
104.2 ± 7.5).
Cell cytotoxicity and apoptosis assays
For MTT cell viability assay, siRNA-transfected HeLa
cells (see above) were seeded on 96-well transparent plates.
The cells were treated with MG-132 for 24 h. Thiazolyl
Blue Tetrazolium Bromide (MTT, Sigma) was added for
additional 60 min in a final concentration of 500 ng/ml.
The medium was removed by suction and MTT crystals
were dissolved in acidic (40 mM HCl) isopropanol. The
absorbance was measured with Infinite 200 microplate
reader (Tecan Group Ltd.) at 570 nm with the reference
wavelength 650 nm.
ATP content measurement was performed using ATP-
Lite kit (PerkinElmer). siRNA-transfected HeLa cells were
seeded on 96-well white plates and treated with MG-132
for 24 h.. Then, 50 ll of mammalian cell lysis solution was
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added to each well containing cells in 100 ll of culture
medium, and the plate was shaken for 5 min in an orbital
shaker at 300 rpm to lyse the cells. Following cell lysis,
50 ll of resuspended, room temperature-adjusted substrate
solution was added to each well and plate was shaken again
for 5 min at 300 rpm. After that, the plate was dark-
adapted and luminescence was measured using SPEC-
TRAFluor Plus (Tecan) microplate reader.
The percentage of dead cells was measured using double
staining with propidium iodide (PI) and Hoechst 33342. For
this, siRNA-transfected cells were seeded on 24-wells plates
and treated with MG-132 for 24 h. Then, 5 lg/ml of Hoechst
33342 was added to the culture media for 30 min, and 1 lg/ml
of PI for the last 5 min. The cells were imaged using micro-
scope and Nikon D5000 camera. To avoid any bias, the pro-
cess of total cells (Hoechst staining) and dead cells (PI
staining) counting was automated using ImageJ software [45].
Using this method, a mean nuclei counts per picture (Hoechst
staining) was 908 for DMSO-treated cells and 443 for MG-
132-treated cells, and mean dead cells count per picture (PI
staining) was 12 for DMSO-treated cells and 59 for MG-132
treated cells. For each data point showed in the graph, nine
photographs were analyzed (three biological replicates per-
formed in three technical replicates; for statistics n = 3).
Caspase 3/7 activity was measured using Caspase-
Glo 3/7 Assay (Promega). siRNA-transfected cells were
seeded on white 96-wells plates and treated with MG-132
for 24 h. Next, 50 ll of Caspase-Glo 3/7 Reagent was
added directly to the wells containing 50 ll medium. The
plates were shaken for 1 min at 300 rpm and kept in the
dark at room temperature for 90 min. Luminescence was
measured with Infinite M200 microplate reader.
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